

Proton pump inhibitors (PPIs) deprescription among the elderly hospitalized in geriatric ward

A.Christiaens^{1,2}, S. Henrard^{1,2,3}, O. Dalleur^{1,3,4}

¹ Clinical Pharmacy research group, Louvain Drug Research Institute, UCLouvain, Brussels, Belgium

² Faculté de pharmacie et sciences biomédicales, UCLouvain

³ Institute of Health and Society (IRSS), UCLouvain, Brussels, Belgium

⁴ Pharmacy Department, Cliniques Universitaires Saint-Luc, Brussels, Belgium

Introduction

Proton pump inhibitors (PPIs) are often **inappropriately prescribed**, leading to **adverse events** for patients and a **significant cost** for the patients and society. **FARMAKA** and the Canadian Deprescribing Network (**deprescribing.org**) developed deprescription algorithms. These tools are available to doctors and pharmacists to help them in the deprescription's process. *"Deprescribing is the planned and supervised process of dose reduction or stopping of medication that might be causing harm, or no longer be of benefit."*

Objectives

To describe the **deprescription opportunities** according to these **algorithms** in a **geriatric hospitalized** patient population.

Methodology

- **Study design:** observational retrospective study
- **Patients:** hospitalized in geriatric ward at Cliniques universitaires Saint-Luc in 2018, with PPI at hospital admission
- **Exclusion criteria:** being included in another clinical study, 2 or more than 2 hospitalizations during the 12 months study, death during hospitalization, palliative care project at the end of the hospitalization, patients transferred from another department

Results




Figure 1: Description of patients

In 2 patients among the 35, the PPI was deprescribed while the deprescribing.org algorithm did not recommend it.




Figure 2: Repartition of deprescription conduction according each algorithms

Conclusion

- Most of the time patients with a PPI are candidate for deprescription
- Deprescription is conducted in less than 1 case out of 3
- The evaluation of barriers to deprescription and the awareness of prescribers and pharmacists about PPI dreprescription could help to reduce inappropriately prescribed PPIs.

References

farmaka.cbip.be
deprescribing.org

Acknowledgments and contacts

Email address: a.christiaens@student.uclouvain.be